Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Rhythm Biosciences Ltd. ( (AU:RHY) ).
Rhythm Biosciences has applied for quotation on the ASX of 2,906,063 new ordinary fully paid shares, which are scheduled to be issued and quoted on March 27, 2026. The additional securities, arising from the exercise or conversion of existing instruments, modestly increase the company’s free float and may enhance liquidity for shareholders while signaling ongoing capital structuring activity.
The move reflects routine capital management rather than a strategic shift, but it slightly expands the company’s equity base and could support future operational or development needs as Rhythm advances its diagnostics portfolio. Investors may view the issuance as a normal part of growth financing for a biotech issuer listed on the Australian market.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd. is an Australia-listed biotechnology company focused on developing diagnostic technologies, operating within the broader life sciences and medical diagnostics industry. Its shares trade on the ASX under the ticker RHY, providing investors exposure to innovation in healthcare testing and related solutions.
Average Trading Volume: 953,979
Technical Sentiment Signal: Buy
Current Market Cap: A$66.37M
Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.